Anti-Mouse CTLA-4 (CD152) [Clone UC10-4F10-11] — Purified in vivo PLATINUM™ Functional Grade

The clone UC10-4F10-11 is used in in vivo mouse studies primarily to neutralize murine CTLA-4 (CD152), thereby blocking the inhibitory effects of CTLA-4 on T cell activation and promoting T cell co-stimulation in immunological experiments.

In detail:

• UC10-4F10-11 is an Armenian hamster IgG monoclonal antibody.
• In in vivo applications, it is injected into mice to block CTLA-4 binding to its B7 co-receptors, preventing negative regulation of T cells and thus allowing for enhanced CD28-mediated T cell co-stimulation.
• This blockade augments the immune response, often in studies investigating immune checkpoint blockade therapies, tumor immunity, or fundamental T cell costimulation biology.
• Beyond in vivo use, UC10-4F10-11 is also validated for flow cytometry and Western blot detection of mouse CTLA-4, but its unique value is for live animal studies where functional blockade of CTLA-4 is required.

While other anti-CTLA-4 clones (like 9H10 and 9D9) can also deplete intra-tumoral regulatory T cells (Tregs), UC10-4F10-11 is primarily characterized as a CTLA-4 neutralizing antibody rather than a depleting one. It is recommended as a robust tool for studying immune checkpoint blockade and can be obtained in low-endotoxin, in vivo-ready formulations for research purposes.

When using UC10-4F10-11 (an anti-mouse CTLA-4 antibody) in research, other commonly used antibodies or proteins include:

• Anti-mouse CTLA-4 antibodies from other clones: 9H10 (Syrian hamster IgG) and 9D9 (mouse IgG2b) are frequently cited alternatives or comparators in literature, with overlapping but distinct mechanisms—especially regarding Treg depletion and neutralization.
• Isotype controls: Armenian hamster IgG isotype controls are typically employed as negative controls during in vivo studies to account for non-specific binding effects.
• CD28 antibodies or proteins: Since CTLA-4 and CD28 have competing roles for the B7 ligands, researchers sometimes use anti-CD28 antibodies to study T cell co-stimulation alongside CTLA-4 blockade.
• Other T cell markers and checkpoint antibodies: Studies commonly utilize antibodies against CD3, CD4, CD8, FoxP3 (for Tregs), and sometimes anti-PD-1 or anti-PD-L1 in combination immunotherapy experiments to profile immune cell populations and checkpoint interplay.
• Secondary detection reagents: For flow cytometry or immunoblot, labeled secondary antibodies targeting Armenian hamster IgG (the isotype for UC10-4F10-11) are used.

In summary, the most commonly referenced antibodies or proteins used with UC10-4F10-11 include other anti-CTLA-4 clones (9H10, 9D9), isotype controls, anti-CD28, and various T cell phenotyping antibodies. Experimental context (e.g., tumor immunity, T cell studies) determines which are prioritized.

Clone UC10-4F10-11 is a widely used monoclonal antibody targeting murine CTLA-4 (CD152), with several key findings and applications documented in the scientific literature:

• Neutralization and Detection: UC10-4F10-11 is an Armenian hamster IgG that neutralizes murine CTLA-4 both in vitro and in vivo. It is effective for Western blot and uniquely validated for flow cytometry—differentiating it in application versatility from other anti-CTLA-4 clones.

• Functional Mechanism: This antibody promotes T cell co-stimulation by blocking CTLA-4’s binding to B7 ligands (CD80/CD86), thus permitting costimulatory signaling via CD28, which enhances T cell activation.

• Immunomodulatory Effects in Disease Models: Injection of UC10-4F10-11 during the priming phase of immune responses has been shown to:

  • Inhibit Th1 memory responses and confer protection in experimental models such as TNBS-induced colitis.
  • Induce the development of CD4^+^ ICOS^high^ T cells that produce higher levels of IL-10 and IL-4, with a concomitant reduction in IFN?, suggesting a shift toward regulatory/Th2-like immune profiles.
  • This effect is dependent on STAT6, implicating Th2 polarization in the skewing of the immune response after anti-CTLA-4 treatment.

• Experimental Applications:

  • UC10-4F10-11 is employed for blocking assays, flow cytometric analysis of CTLA-4 expression, and functional studies of T cell activation and regulation in murine models.
  • The antibody is produced to high purity standards and is commonly used as a reference clone for assessing CTLA-4 function and immune modulation.

In summary, scientific literature cites clone UC10-4F10-11 as a reliable tool for both mechanistic studies of CTLA-4 in mouse models and for inducing regulatory or Th2-biased immune responses, especially during experimental manipulations of immune priming and disease models.

Dosing regimens of clone UC10-4F10-11 for in vivo mouse models generally range from 50 to 250?µg per mouse per dose, but precise dosing may vary based on mouse strain, experimental context, and disease model.

• The recommended range for in vivo studies is 50–250?µg per mouse per administration. This guidance is based on recent publication data, but it is important that each investigator optimizes dosing for their specific application and model.
• The dosing can be adjusted according to the experimental design (e.g., tumor models, transgenic or knockout lines, autoimmune or immunization protocols). For example, studies involving genetic knockout mice (such as Tcf7^fl/fl^; CD8a^Cre^+) administering anti-CTLA-4 commonly use regimens similar to the recommended range, but the schedule (number, frequency, and timing of doses) may differ depending on the hypothesis tested (e.g., memory formation, effector response).
• Published examples show that UC10-4F10-11 is frequently given at the time of immunization or challenge, sometimes repeated at intervals tailored to maximize immune modulation or tumor control.

Key considerations affecting dosing:

• Mouse model type: Transgenic, knockout, cancer (e.g., B16F10 melanoma), infectious, or autoimmunity.
• Disease context: Tumor studies may involve repeated dosing; immunization or autoimmune studies could involve fewer, timing-specific injections.
• Formulation and route: Intraperitoneal injection is most common; low endotoxin formulations are recommended for sensitive or long-term studies.
• Isotype control: Always pair with an appropriate isotype control for proper experimental interpretation.

Summary Table: UC10-4F10-11 dosing guidance

These regimens are not fixed and should be empirically determined for each unique mouse model and study design. Investigators should consult the most recent literature for similar experimental setups to guide fine-tuning of dose and schedule.